Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma
Open Access
- 1 October 2002
- Vol. 57 (10), 865-868
- https://doi.org/10.1136/thorax.57.10.865
Abstract
Background: With the transition to hydrofluoroalkane-134a propellants in metered dose inhalers, it is important to consider the efficacy and safety profiles of formulations containing inhaled corticosteroids. We examined the airway and systemic effects of hydrofluoroalkane-134a fluticasone propionate (FLU-HFA) and beclomethasone dipropionate (BEC-HFA) at recommended labelled doses. Methods: Twenty mild to moderate asthmatics were randomised in crossover fashion to receive 6 weeks of 500 μg/day followed by 1000 μg/day FLU-HFA and BEC-HFA. Measurements were made at baseline after placebo run in and washout, and after each randomised treatment. The primary airway outcome for benefit was the dose of methacholine provoking a fall in forced expiratory volume in 1 second (FEV1) of 20% or more (methacholine PD20) and for systemic adverse effects was overnight urinary cortisol/creatinine (OUCC). Results: For mean responses, both doses of BEC-HFA and FLU-HFA produced significant improvements in PD20 compared with baseline. The improvement was not significantly greater with 1000 μg/day FLU-HFA versus BEC-HFA, a 1.69 fold difference (95% CI 0.94 to 3.04). Both doses of BEC-HFA but not FLU-HFA caused significant suppression of OUCC compared with baseline, with significantly (pConclusion: There was no difference in the airway and systemic effects in patients with mild to moderate asthma between FLU-HFA and BEC-HFA at a dose of 500 μg/day. At 1000 μg/day there was increased systemic bioactivity with BEC-HFA compared with FLU-HFA, without any gain in airway efficacy.Keywords
This publication has 21 references indexed in Scilit:
- Influences on plasma cortisol of different formulations of beclomethasone dipropionateBritish Journal of Clinical Pharmacology, 2000
- Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover studyThe Lancet, 2000
- Pharmaceutical transition to non-CFC pressurized metered dose inhalersRespiratory Medicine, 2000
- From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.2000
- Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.2000
- Dose–response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthmaAmerican Journal Of Medicine, 2000
- Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionateBritish Journal of Clinical Pharmacology, 1999
- A Controlled Trial of Chlorofluorocarbon-Free Triamcinolone Acetonide Inhalation Aerosol in the Treatment of Adult Patients With Persistent AsthmaChest, 1999
- Differences in lung bioavailability between different propellants for fluticasone propionateThe Lancet, 1999
- Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens.Thorax, 1995